Susquehanna International Group, LLP Nurix Therapeutics, Inc. Call Options Transaction History
Susquehanna International Group, LLP
- $688 Billion
 - Q2 2025
 
Call Options
	  13 transactions
	
  Others Institutions Holding NRIX
# of Institutions
175Shares Held
79.5MCall Options Held
126KPut Options Held
11.3K- 
    
      Black Rock Inc. New York, NY6.82MShares$87.2 Million0.0% of portfolio
 - 
    
      Deep Track Capital, LP Greenwich, CT6.06MShares$77.5 Million2.45% of portfolio
 - 
    
      Vanguard Group Inc Valley Forge, PA4.47MShares$57.1 Million0.0% of portfolio
 - 
    
      Commodore Capital LP New York, NY3.95MShares$50.5 Million4.19% of portfolio
 - 
    
      Baker Bros. Advisors LP New York, NY3.88MShares$49.6 Million0.45% of portfolio
 
About Nurix Therapeutics, Inc.
- Ticker NRIX
 - Exchange NASDAQ
 - Sector Healthcare
 - Industry Biotechnology
 - Shares Outstandng 47,147,800
 - Market Cap $603M
 - Description
 - Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...